Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Study to evaluate effectiveness of hypoglossal nerve stimulation
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Subscribe To Our Newsletter & Stay Updated
